Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Urol. 2013 May;23(3):194-200. doi: 10.1097/MOU.0b013e32835e9f1a.

The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.

Author information

1
Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia bThe Division of Urology, University of Montreal Hospital Center (CHUM), University of Montreal, Montreal, Quebec, Canada.

Abstract

PURPOSE OF REVIEW:

To present the recent advances in novel agents that target heat shock proteins (Hsps) to treat or delay the development of castration resistant prostate cancer (CRPC).

RECENT FINDINGS:

Multiple preclinical studies have shown that silencing Hsp27, Hsp90, or clusterin sensitizes prostate cancer cells to modern chemotherapy and radiation treatments; and overexpression of these chaperones confers resistance to these therapies. Antisense oligonucleotides targeting Hsp27 and clusterin have shown good biological activity in human phase II trials and phase III studies are ongoing. Despite promising preclinical efficacy, a number of phase I/II human trials with various Hsp90 inhibitors have been disappointing with negligible anticancer activity and dose-limiting toxicity profiles. Newer Hsp90 inhibitors with better toxicity profiles, and inhibitors that target Hsp90 cofactors, such as FKBP52, are currently being investigated in human studies.

SUMMARY:

Many Hsp chaperone client proteins are key components of alternative growth factor pathways upregulated in CRPC and are involved in key resistance pathways to current chemotherapy and radiotherapy regimes. New treatments that inhibit Hsps are attractive anticancer strategies as they have the ability to simultaneously target multiple pathways involved in CRPC.

PMID:
23385973
DOI:
10.1097/MOU.0b013e32835e9f1a
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center